-
Posted by
Two Blokes 12 hours ago -
Filed in
Stock
-
0 views
GSK PLC (LSE:GSK, NYSE:GSK) reported earnings ahead of expectations and kept full-year guidance intact, even though sales of vaccines softened. The FTSE 10-listed drugmaker reported a 6.1% fall in vaccine sales to £2.10 billion, which was almost in line with the $2.11 billion average City forecast.
